RECIST 1.1 Compared With RECIST 1.0 in Patients With Advanced Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Targeted Therapy

OBJECTIVE: Response Evaluation Criteria in Solid Tumors (RECIST) is the most widely accepted method to objectively assess response to therapy in renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)–targeted therapy. Both RECIST 1.0 and 1.1 have been used to assess respon...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:AJR Am J Roentgenol
Huvudupphovsmän: Krajewski, Katherine M., Nishino, Mizuki, Ramaiya, Nikhil H., Choueiri, Toni K.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2015
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4352691/
https://ncbi.nlm.nih.gov/pubmed/25714313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2214/AJR.14.13236
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk